Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:8/27/2010

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 10,000 shares of common stock to two new employees.

Both of the stock options are intended to be incentive stock options to the extent permitted by law and both have an exercise price per share equal to $4.53, the fair market value on the grant date. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee’s continued service relationship with the Company on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

Both stock options were granted as an inducement material to the new employees entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave(R). The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approach
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
2. Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
3. Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
4. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
5. Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
6. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
7. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
9. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
11. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 18, 2014 According ... (Surface & Intravascular Systems- Warming & Cooling), Application ... (Surgeon & Anesthesiologist, Nursing & Paramedical Staff) - ... MarketsandMarkets, this report studies the global Temperature Management Market ... The market is expected to reach $2.5 Billion ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... for innovation, increasing clinical development costs, new technologies ... fast-changing environment are important factors driving industry change. ... trial costs continue to rise due to a ... conducted by industry think tanks suggest each day ...
(Date:9/18/2014)... , Sept. 18, 2014  Decision Resources Group ... endothelial growth factor (VEGF) agent for wet AMD, is ... Advantage plans as Genentech,s Lucentis, which is the standard ... managed care organization (MCO) directors do not identify a ... slightly more likely than Lucentis to be listed on ...
Breaking Medicine Technology:Temperature Management Market Worth $2.5 Billion by 2019 2Temperature Management Market Worth $2.5 Billion by 2019 3Temperature Management Market Worth $2.5 Billion by 2019 4Patient Recruitment in Asia Biotech and Pharma Companies 2Patient Recruitment in Asia Biotech and Pharma Companies 3Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 2Regeneron's Eylea and Genentech's Lucentis Are Equally Likely to be Covered on Commercial and Medicare Advantage Plans for Wet AMD 3
... , NEW BRUNSWICK, N.J., Nov. 12 Senesco ... SNT ) announced today that Catherine Taylor, ... presenting pre-clinical stability and biological activity data on ... 2009 American Association for Cancer Research (AACR)-National Cancer ...
... Thoratec Corporation (Nasdaq: THOR ), a world leader ... and restore failing hearts, said today that it will ... HeartMate II Destination Therapy clinical trial that will be ... the American Heart Association(AHA) Scientific Sessions 2009. , The ...
Cached Medicine Technology:Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 2Senesco Presents Pre-Clinical Stability and Biological Activity Data on SNS-01 at the 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference 3
(Date:9/19/2014)... September 19, 2014 VogueQueen.com ... dresses that will make ladies more beautiful at their ... that everyone can afford. The company’s new products are ... providing offering great savings for all the global clients. ... are extremely beautiful. I have ordered several items on ...
(Date:9/18/2014)... 2014 Defendants in more than ... pending in Pennsylvania’s Philadelphia Court of Common Pleas ... behalf of out-of-state plaintiffs dismissed, Bernstein Liebhard LLP ... the defendants maintain that circumstances surrounding the alleged ... have no connection to Pennsylvania. The filings did ...
(Date:9/18/2014)... ON (PRWEB) September 18, 2014 Dr. ... Plastic Surgeon with the American Academy of Facial Plastic ... of Toronto in the Division of Facial Plastic Surgery. ... work in facial plastic surgery. , Dr. Ellis ... foremost, he will be presenting on injection techniques and ...
(Date:9/18/2014)... Exposure to diverse communities may boost infants, social learning, ... languages in the park or supermarket could help children ... are different from them, researchers found. "Research ... against interacting with and learning from people who are ... Chicago psychology professor, said in a university news release. ...
(Date:9/18/2014)... 18, 2014 "Medical staff need better ... also maintaining the patient's privacy," said one of two ... idea in order to supply caregivers with the equipment ... created a prototype for The Helper to make it ... to turn patient onto his or her side. It ...
Breaking Medicine News(10 mins):Health News:VogueQueen.com’s New Line Of Cheap Wedding Dresses Aims To Attract Chic Ladies 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Defendants Seek to Have Pennsylvania Claims Filed by Out-of-State Plaintiffs Dismissed, Bernstein Liebhard LLP Reports 3Health News:Dr. David A. F. Ellis Has Been Invited to Speak at a Conference of the American Academy of Facial Plastic and Reconstructive Surgery in Orlando, Florida 2Health News:Study: Exposure to Diversity Might Boost Baby's Social Skills 2
... TSX: COM , VANCOUVER, Nov. 6 /PRNewswire-FirstCall/ - Cardiome ... announced that it will report financial results for the third ... November 9, 2009. Cardiome will hold a teleconference call and ... discuss the results. , To access the conference call, please ...
... The Leukemia & Lymphoma Society (LLS) will again be participating ... two campaigns this past spring and summer, garnered more than $1 ... and support services. , During the campaign, taking place from November ... discount coupons participants can use (in-store only) at all ...
... , WASHINGTON, Nov. 6 The U.S. bishops sent an ... as House members steeped themselves in debate over procedures related ... before meeting to discuss proposed amendments to the bill, the ... of "an amendment to keep in place current federal law ...
... VA)--Three leading scientific organizations specializing in infectious diseases ... expressing their significant concern with current federal guidance ... by healthcare workers in treating suspected or confirmed ... Society for Healthcare Epidemiology of America (SHEA), the ...
... researcher says , FRIDAY, Nov. 6 (HealthDay News) -- New ... within five years of developing the disease are more likely ... others with the condition. , The findings, published Nov. 4 ... who relapse within five years of developing it are nearly ...
... ... Product Lines , ... (PRWEB) November 6, 2009 -- WAV, Inc., the value-added distributor of ... with Vecima Networks Inc. (TSX:VCM), a leading provider of equipment supporting broadband access ...
Cached Medicine News:Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3Health News:Get a Jump on Your Holiday Shopping and Give Two Gifts This Season: One to Your Loved Ones and One to People Battling Blood Cancer 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 2Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 3Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 4Health News:Bishops to House: Keep Abortion Funding Out of Health Care Reform, Make Health Care Available to Vulnerable 5Health News:Prevention experts urge modification to 2009 H1N1 guidance for health care workers 2Health News:Early Relapse of MS May Mean Fewer Issues Later 2Health News:WAV Distribution Partners with Vecima Networks Inc. 2Health News:WAV Distribution Partners with Vecima Networks Inc. 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: